Journal of Gastroenterology

, Volume 46, Issue 4, pp 421–431 | Cite as

Mucosal inflammation as a potential etiological factor in irritable bowel syndrome: a systematic review

  • Alexander C. Ford
  • Nicholas J. Talley



The causes of irritable bowel syndrome (IBS) remain obscure. Some investigators have proposed chronic low-grade mucosal inflammation as a potential etiological factor. We performed a systematic review to examine this issue in detail.


MEDLINE, EMBASE, and EMBASE classic were searched up to December 2010 to identify studies of case–control design applying tests for low-grade inflammation to either full-thickness intestinal or endoscopic mucosal biopsies from patients with IBS. Controls were required to be healthy individuals, or asymptomatic patients undergoing investigation for reasons other than the reporting of upper or lower gastrointestinal symptoms. Individual study results were summarized descriptively.


The literature search identified 1388 citations, of which 16 studies were eligible for inclusion. Individual study results were diverse, partly as a consequence of the different surrogate markers for inflammatory mechanisms studied. Mast cells, T lymphocytes, B lymphocytes, and mucosal cytokine production all appeared altered among cases with IBS in individual studies, while no study demonstrated a significant difference in numbers of plasma cells, neutrophils, or eosinophils. Some studies suggested a relationship between mast cell abnormalities and symptom severity and frequency, as well as co-existent fatigue and depression. Studies were limited by the lack of comparability of controls, and the fact that most were conducted in highly selected groups of patients with IBS.


Low-grade mucosal inflammation, particularly mast cell activation, may be a contributory factor in the pathogenesis of IBS. Mast cell stabilizers warrant further assessment as a potential therapy in the condition.


Irritable bowel syndrome Inflammation Mast cells T lymphocytes 


  1. 1.
    Longstreth GF, Thompson WG, Chey WD, et al. Functional bowel disorders. Gastroenterology. 2006;130:1480–91.PubMedCrossRefGoogle Scholar
  2. 2.
    Agreus L, Talley NJ, Svardsudd K, et al. Identifying dyspepsia and irritable bowel syndrome: the value of pain or discomfort, and bowel habit descriptors. Scand J Gastroenterol. 2000;35:142–51.PubMedCrossRefGoogle Scholar
  3. 3.
    Hillila MT, Farkkila MA. Prevalence of irritable bowel syndrome according to different diagnostic criteria in a non-selected adult population. Aliment Pharmacol Ther. 2004;20:339–45.PubMedCrossRefGoogle Scholar
  4. 4.
    Hungin APS, Whorwell PJ, Tack J, et al. The prevalence, patterns and impact of irritable bowel syndrome: an international survey of 40,000 subjects. Aliment Pharmacol Ther. 2003;17:643–50.PubMedCrossRefGoogle Scholar
  5. 5.
    Mearin F, Badia X, Balboa A, et al. Irritable bowel syndrome prevalence varies enormously depending on the employed diagnostic criteria: comparison of Rome II versus previous criteria in a general population. Scand J Gastroenterol. 2001;36:1155–61.PubMedCrossRefGoogle Scholar
  6. 6.
    Agreus L, Svardsudd K, Nyren O, et al. Irritable bowel syndrome and dyspepsia in the general population: overlap and lack of stability over time. Gastroenterology. 1995;109:671–80.PubMedCrossRefGoogle Scholar
  7. 7.
    Ford AC, Forman D, Bailey AG, et al. Irritable bowel syndrome: a 10-year natural history of symptoms, and factors that influence consultation behavior. Am J Gastroenterol. 2008;103:1229–39.PubMedCrossRefGoogle Scholar
  8. 8.
    Halder SLS, Locke GR III, Schleck CD, et al. Natural history of functional gastrointestinal disorders: a 12-year longitudinal population-based study. Gastroenterology. 2007;133:799–807.PubMedCrossRefGoogle Scholar
  9. 9.
    Kalantar JS, Locke GR, Zinsmeister AR, et al. Familial aggregation of irritable bowel syndrome: a prospective study. Gut. 2003;52:1703–7.PubMedCrossRefGoogle Scholar
  10. 10.
    Stanghellini V, Tosetti C, Barbara G, et al. Dyspeptic symptoms and gastric emptying in the irritable bowel syndrome. Am J Gastroenterol. 2002;97:2738–43.PubMedCrossRefGoogle Scholar
  11. 11.
    Cann PA, Read NW, Brown C, et al. Irritable bowel syndrome: relationship of disorders in the transit of a single solid meal to symptom patterns. Gut. 1983;24:405–11.PubMedCrossRefGoogle Scholar
  12. 12.
    Moriarty KJ, Dawson AM. Functional abdominal pain: further evidence that whole gut is affected. Br Med J. 1982;284:1670–2.CrossRefGoogle Scholar
  13. 13.
    Trimble KC, Farouk R, Pryde A, et al. Heightened visceral sensation in functional gastrointestinal disease is not site-specific. Evidence for a generalized disorder of gut sensitivity. Dig Dis Sci. 1995;40:1607–13.PubMedCrossRefGoogle Scholar
  14. 14.
    Tillisch K, Mayer EA, Labus JS. Quantitative meta-analysis identifies brain regions activated during rectal distension in irritable bowel syndrome. Gastroenterology. 2011;140:91–100. doi: 10.1053/j.gastro.2010.07.053.PubMedCrossRefGoogle Scholar
  15. 15.
    Collins SM. Is the irritable gut an inflamed gut? Scand J Gastroenterol. 1992;192(suppl):102–5.CrossRefGoogle Scholar
  16. 16.
    Marshall JK, Thabane M, Borgaonkar MR, et al. Postinfectious irritable bowel syndrome after a food-borne outbreak of gastroenteritis attributed to a viral pathogen. Clin Gastroenterol Hepatol. 2007;5:457–60.PubMedCrossRefGoogle Scholar
  17. 17.
    Marshall JK, Thabane M, Garg AX, et al. Eight year prognosis of postinfectious irritable bowel syndrome following waterborne bacterial dysentery. Gut. 2010;59:605–11.PubMedCrossRefGoogle Scholar
  18. 18.
    Mearin F, Perez-Oliveras M, Perello A, et al. Dyspepsia and irritable bowel syndrome after a Salmonella gastroenteritis outbreak: one year follow-up cohort study. Gastroenterology. 2005;(129):98–104.CrossRefGoogle Scholar
  19. 19.
    Tornblom H, Holmvall P, Svenungsson B, et al. Gastrointestinal symptoms after infectious diarrhea: a five-year follow-up in a Swedish cohort of adults. Clin Gastroenterol Hepatol. 2007;5:461–4.PubMedCrossRefGoogle Scholar
  20. 20.
    Wang LH, Fang XC, Pan GZ. Bacillary dysentery as a causative factor of irritable bowel syndrome and its pathogenesis. Gut. 2004;53:1096–101.PubMedCrossRefGoogle Scholar
  21. 21.
    Mearin F, Perello A, Balboa A, et al. Pathogenic mechanisms of postinfectious functional gastrointestinal disorders: results 3 years after gastroenteritis. Scand J Gastroenterol. 2009;44:1173–85.PubMedCrossRefGoogle Scholar
  22. 22.
    Weston AP, Biddle WL, Bhatia PS, et al. Terminal ileal mucosal mast cells in irritable bowel syndrome. Dig Dis Sci. 1993;38:1590–5.PubMedCrossRefGoogle Scholar
  23. 23.
    Barbara G, Stanghellini V, De Giorgio R, et al. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology. 2004;126:693–702.PubMedCrossRefGoogle Scholar
  24. 24.
    Barbara G, Wang B, Stanghellini V, et al. Mast cell-dependent excitation of visceral-nociceptive sensory neurons in irritable bowel syndrome. Gastroenterology. 2007;132:26–37.PubMedCrossRefGoogle Scholar
  25. 25.
    Bian ZX, Li Z, Huang ZX, et al. Unbalanced expression of protease-activated receptors-1 and -2 in the colon of diarrhea-predominant irritable bowel syndrome patients. J Gastroenterol. 2009;44:666–74.PubMedCrossRefGoogle Scholar
  26. 26.
    Cenac N, Andrews CN, Holzhausen M, et al. Role for protease activity in visceral pain in irritable bowel syndrome. J Clin Invest. 2007;117:636–47.PubMedCrossRefGoogle Scholar
  27. 27.
    Chadwick V, Chen W, Shu D, et al. Activation of the mucosal immune system in irritable bowel syndrome. Gastroenterology. 2002;122:1778–83.PubMedCrossRefGoogle Scholar
  28. 28.
    Choung RS, Faubion WA, Saito YA et al. Cytokine expression in colonic mucosa and plasma in patients with irritable bowel syndrome. Neurogastroenterol Motil. 2010;22 (Suppl S1):57.Google Scholar
  29. 29.
    Coeffier M, Gloro R, Boukhettala N, et al. Increased proteasome-mediated degradation of occludin in irritable bowel syndrome. Am J Gastroenterol. 2010;105:1181–8.PubMedCrossRefGoogle Scholar
  30. 30.
    Cremon C, Gargano L, Morselli-Labate AM, et al. Mucosal immune activation in irritable bowel syndrome: gender-dependence and association with digestive symptoms. Am J Gastroenterol. 2009;104:392–400.PubMedCrossRefGoogle Scholar
  31. 31.
    Forshammar J, Isaksson S, Strid H, et al. A pilot study of colonic B cell pattern in irritable bowel syndrome. Scand J Gastroenterol. 2008;43:1461–6.PubMedCrossRefGoogle Scholar
  32. 32.
    Guilarte M, Santos J, de Torres I, et al. Diarrhoea-predominant IBS patients show mast cell activation and hyperplasia in the jejunum. Gut. 2007;56:203–9.PubMedCrossRefGoogle Scholar
  33. 33.
    Lee KJ, Kim YB, Kim JH, et al. The alteration of enterochromaffin cell, mast cell, and lamina propria T lymphocyte numbers in irritable bowel syndrome and its relationship with psychological factors. J Gastroenterol Hepatol. 2008;23:1689–94.PubMedCrossRefGoogle Scholar
  34. 34.
    MacSharry J, O’Mahony L, Fanning A, et al. Mucosal cytokine imbalance in irritable bowel syndrome. Scand J Gastroenterol. 2008;43:1467–76.PubMedCrossRefGoogle Scholar
  35. 35.
    O’Sullivan M, Clayton N, Breslin NP, et al. Increased mast cells in the irritable bowel syndrome. Neurogastroenterol Motil. 2000;12:449–57.PubMedCrossRefGoogle Scholar
  36. 36.
    Piche T, Saint-Paul MC, Dainese R, et al. Mast cells and cellularity of the colonic mucosa correlated with fatigue and depression in irritable bowel syndrome. Gut. 2008;57:468–73.PubMedCrossRefGoogle Scholar
  37. 37.
    Tornblom H, Lindberg G, Nyberg B, et al. Full-thickness biopsy of the jejunum reveals inflammation and enteric neuropathy in irritable bowel syndrome. Gastroenterology. 2002;123:1972–9.PubMedCrossRefGoogle Scholar
  38. 38.
    Walker MM, Talley NJ, Prabhakar M, et al. Duodenal mastocytosis, eosinophilia, and intraepithelial lymphocytosis as possible disease markers in the irritable bowel syndrome and functional dyspepsia. Aliment Pharmacol Ther. 2009;29:765–73.PubMedCrossRefGoogle Scholar
  39. 39.
    Lijmer JG, Mol BW, Heisterkamp S. Empirical evidence of design-related bias in studies of diagnostic tests. JAMA. 1999;282:1061–6.PubMedCrossRefGoogle Scholar
  40. 40.
    Marshall JK, Thabane M, Garg AX, et al. Intestinal permeability in patients with irritable bowel syndrome after a waterborne outbreak of acute gastroenteritis in Walkerton, Ontario. Aliment Pharmacol Ther. 2004;20:1317–22.PubMedCrossRefGoogle Scholar
  41. 41.
    Pimentel M, Lembo A, Chey WD, et al. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med. 2011;364:22–32.PubMedCrossRefGoogle Scholar
  42. 42.
    Ford AC, Marwaha A, Lim A, et al. Systematic review and meta-analysis of the prevalence of irritable bowel syndrome in individuals with dyspepsia. Clin Gastroenterol Hepatol. 2010;8:401–9.PubMedCrossRefGoogle Scholar
  43. 43.
    Lembo AJ, Neri B, Tolley J, et al. Use of serum biomarkers in a diagnostic test for irritable bowel syndrome. Aliment Pharmacol Ther. 2009;29:834–42.PubMedCrossRefGoogle Scholar
  44. 44.
    Klooker TK, Braak B, Koopman KE, et al. The mast cell stabiliser ketotifen decreases visceral hypersensitivity and improves intestinal symptoms in patients with irritable bowel syndrome. Gut. 2010;59:1213–21PubMedCrossRefGoogle Scholar

Copyright information

© Springer 2011

Authors and Affiliations

  1. 1.Leeds Gastroenterology Institute, D Floor, Clarendon WingLeeds General InfirmaryLeedsUK
  2. 2.Leeds Institute of Molecular MedicineLeeds UniversityLeedsUK
  3. 3.Faculty of HealthUniversity of NewcastleNew South WalesAustralia

Personalised recommendations